H.C. Wainwright Sticks to Its Buy Rating for Cogent Biosciences (COGT)
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Cogent Biosciences (COGT) with a $55 price target. The firm highlights Burns' strong track record, including an 18.9% average return. Additionally, Stifel Nicolaus maintained its Buy rating on the stock in June with a lower $45 price target.
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Cogent Biosciences today and set a price target of $55.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Burns is a 5-star analyst with an average return of 18.9% and a 45.58% success rate. Burns covers the Healthcare sector, focusing on stocks such as Caribou Biosciences, Cardiff Oncology, and Zymeworks.
In a report released on June 15, Stifel Nicolaus also maintained a Buy rating on the stock with a $45.00 price target.